



Supporting Information (Appendix S1-S4)

Appendix S1




Individual plasma sodium profile for the patients with non-cirrhotic prehepatic portal hypertension and a ≥ 5 mmol/l decrease in plasma sodium. Profiles are normalized to the day of discontinuation. *The patient who suffered from myelinolysis (dark blue profile).*

Appendix S2 and S3



Change in plasma sodium during terlipressin treatment by cumulative dose (left) and number of days of treatment (right).
●: Non-cirrhotic prehepatic portal hypertension ○: Cirrhotic portal hypertension

Appendix S4



Change in plasma sodium during terlipressin treatment by baseline plasma sodium.
●: Non-cirrhotic prehepatic portal hypertension ○: Cirrhotic portal hypertension
Spearman's rank correlation coefficient: Non-cirrhotic prehepatic portal hypertension ($\rho=-0.25$, $p=0.46$), Cirrhotic portal hypertension ($\rho=-0.40$, $p<0.0001$)